Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
PAFSC’s 1st Committee Recommends Approval for Pfizer’s OAB Drug Toviaz
The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) First Committee on Drugs on October 26 recommended approval for four products/indications, including Pfizer Japan’s overactive bladder (OAB) treatment Toviaz Tablets 4 mg/8 mg (fesoterodine fumarate). Early post-marketing phase vigilance (EPPV) will…
To read the full story
REGULATORY
- Japan Panel Green-Lights GSK’s Hep B Drug, Brinsupri, Hyrnuo
July 28, 2026
- Japanese Women Top Life Expectancy for 41st Year Running
July 28, 2026
- MHLW Sets FY2027 Budget Priorities for Drug Discovery, Advanced Medicine
July 28, 2026
- Japan Enacts Revised Immunization Act, Opens Way for RSV Antibodies under NIP
July 27, 2026
- PMDA Sees Drop in Japan-China Bilateral Regulatory Exchanges
July 27, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…